- Reports continued progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare disease - - New data from pilot phase of ongoing CheMo4METPANC Phase 2b combination trial of motixafortide in PDAC, sponsored by Columbia University, to be presented at upcoming 2025 ASCO Annual Meeting – - APHEXDA performing well under Ayrmid stewardship - - Management to host conference call today, May 27th, at 8:30 am EDT - TEL AVIV, Israel, May 27, 2025 /PRNewswire/ -- Bi ...

Core Insights - BioLineRx Ltd. has made significant progress in evaluating assets for potential in-licensing and development in oncology and rare diseases [1] - The company executed a licensing agreement with Ayrmid Pharma Ltd. for APHEXDA® (motixafortide), which includes a $10 million upfront payment, up to $87 million in commercial milestones, and high double-digit royalties on net sales [1][5] - BioLineRx completed financings that raised a total of $19 million and reduced its operating expense run rate by 70%, extending its cash runway through the second half of 2026 [1][2] Corporate Updates - The CEO of BioLineRx highlighted a strategic shift with the exclusive licensing agreement with Ayrmid Ltd., which allows commercialization of APHEXDA® in non-solid tumor indications outside Asia [2] - The company has implemented cost efficiencies, including shutting down U.S. commercial operations, leading to a significant reduction in operating expenses [2] - BioLineRx is focused on in-licensing additional assets over the next year to advance through clinical proof-of-concept, funded by milestones and royalties from out-licensing transactions [2] Financial Updates - For the year ended December 31, 2024, BioLineRx reported revenues of $28.9 million, a 502.1% increase from $4.8 million in 2023, primarily due to licensing agreements and product sales [10] - The cost of revenues for 2024 was $9.3 million, up 151.4% from $3.7 million in 2023, reflecting amortization of intangible assets and royalties on net product sales [10] - Research and development expenses decreased by 26.4% to $9.2 million in 2024, while sales and marketing expenses decreased by 6.7% to $23.6 million [10] - The net loss for 2024 was $9.2 million, significantly reduced from $60.6 million in 2023 [10] Clinical Updates - The company activated additional trial sites for the CheMo4METPANC Phase 2b clinical trial for motixafortide, with full enrollment of 108 patients expected by 2027 [4] - The first patient was dosed in a Phase 1 clinical trial evaluating motixafortide for mobilization of CD34+ hematopoietic stem cells for gene therapies in Sickle Cell Disease [10]